These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29850358)

  • 41. Urticarial vasculitis associated with a monoclonal IgM gammopathy: Schnitzler's syndrome.
    Borradori L; Rybojad M; Puissant A; Dallot A; Verola O; Morel P
    Br J Dermatol; 1990 Jul; 123(1):113-8. PubMed ID: 2117969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.
    Rondeau JM; Ramage P; Zurini M; Gram H
    MAbs; 2015; 7(6):1151-60. PubMed ID: 26284424
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urticarial lesions and monoclonal IgM gammopathy. Schnitzler's syndrome.
    Sanmartín O; Febrer I; Botella R; Grau M; de la Cuadra J; Aliaga A
    Arch Dermatol; 1994 Sep; 130(9):1195, 1198. PubMed ID: 8085880
    [No Abstract]   [Full Text] [Related]  

  • 44. [A woman with recurrent urticaria, joint pain and fever].
    Gran JT; Midtvedt Ø; Haug S
    Tidsskr Nor Laegeforen; 2011 Jan; 131(2):135-6. PubMed ID: 21267032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of CCL2 with systemic inflammation in Schnitzler syndrome.
    Krause K; Sabat R; Witte-Händel E; Schulze A; Puhl V; Maurer M; Wolk K
    Br J Dermatol; 2019 Apr; 180(4):859-868. PubMed ID: 30339714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial.
    Cascavilla N; Bisceglia M; D'Arena G
    Int J Immunopathol Pharmacol; 2010; 23(2):633-6. PubMed ID: 20646359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
    Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
    Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Schnitzler's syndrome. A new case].
    Paulin P; Cusset C; Jacquelin L; Pages JM; Chapalain JC
    Presse Med; 1992 Nov; 21(37):1758-61. PubMed ID: 1488421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.
    Krause K; Tsianakas A; Wagner N; Fischer J; Weller K; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Apr; 139(4):1311-1320. PubMed ID: 27658762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Schnitzler's syndrome treated successfully with intravenous pulse cyclophosphamide.
    Peterlana D; Puccetti A; Tinazzi E; Simeoni S; Lunardi C
    Scand J Rheumatol; 2005; 34(4):328-30. PubMed ID: 16195169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Schnitzler's syndrome (urticaria and macroglobulinemia) dramatically improved with corticosteroids.
    Goupille P; Pizzuti P; Diot E; Jattiot F; Guilmot JL; Valat JP
    Clin Exp Rheumatol; 1995; 13(1):95-8. PubMed ID: 7774112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
    Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
    Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The Schnitzler syndrome as a cause of recurrent fever of unknown origin].
    Winckelmann G; Nagel HG; Maier R; Reuther G
    Dtsch Med Wochenschr; 1996 Jul; 121(27):860-4. PubMed ID: 8681741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
    Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease.
    Galozzi P; Baggio C; Bindoli S; Oliviero F; Sfriso P
    Front Pharmacol; 2018; 9():1074. PubMed ID: 30298010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Sensitive chronic inflammatory demyelinating polyradiculoneuropathy in Schnitzler's syndrome].
    Blaise S; Vallat JM; Tabaraud F; Bonnetblanc JM
    Ann Dermatol Venereol; 2003 Mar; 130(3):348-51. PubMed ID: 12746673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Schnitzler's syndrome versus adult onset Still's disease.
    Tomková H; Shirafuji Y; Arata J
    Eur J Dermatol; 1998 Mar; 8(2):118-21. PubMed ID: 9649652
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Canakinumab for the treatment of hyperimmunoglobulin D syndrome.
    Sánchez-Manubens J; Iglesias E; Anton J
    Expert Rev Clin Immunol; 2019 Mar; 15(3):215-220. PubMed ID: 30652926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlative bone imaging in a case of Schnitzler's syndrome and brief review of the literature.
    Willekens I; Walgraeve N; Goethals L; De Geeter F
    Hell J Nucl Med; 2015; 18(1):71-3. PubMed ID: 25840575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.